tbuckley/cabot-search huggingface dataset:
The state of free radical oxidation in the tissue of primary vulvar cancer and of its recurrence.
Authors: Ekaterina Igorevna Surikova, Irina Aleksandrovna Goroshinskaya, Galina Andreevna Nerodo, Ekaterina Alekseevna Nerodo, Elena Vladimirovna Shalashnaya, Anastasia Victorovna Leonova
Journal: Journal of Clinical Oncology (2014)

e22234 Background: Study of the activity of various links of antioxidant system in the tissue of vulvar cancer and recurrence of vulvar cancer. Methods: The activity of superoxide dismutase (SOD), catalase, glutathione peroxidase (GPO), glutathione reductase (GR), and the content of reduced glutathione (GSH) were studied by conventional methods in the cancer tissue and recurrence of the vulva, as well as in healthy tissue samples (taken along the line of resection) obtained in the surgical treatment of 16 patients with cancer of the vulva stage II-III (squamous cell carcinoma). The neoadjuvant chemotherapy at these patients was missed. Results: Analysis of the data obtained showed that in vulvar cancer tissue the activity of antioxidant enzymes was significantly higher: SOD - 2 times, GPO - 4 times compared with the activity in healthy tissue, while catalase activity did not change. GSH content increased significantly - 8.9 times, whereas the activity of GR increased only 3.3-fold compared to the level in healthy tissue. At the same time in recurrent vulvar cancer tissue SOD, catalase and GPO was not different from the activity of these enzymes in normal tissue, GSH content was 2.3 times higher, and the activity of GR was increased by 31.1% compared to the level in healthy tissue. In comparison with the tissue of the primary tumor in the tissue of the vulva cancer recurrence the activity of antioxidant and glutathione-dependent enzymes was significantly lower: SOD - 2.1 times, catalase - 1.9 times, GPO - 2.7 times, GR – 2.1 times. Also in recurrent tumor 4.0 times lower contents of GSH relative to the level in the primary tumor was observed. Conclusions: Preliminary results showed that in the tissue of local recurrence of a vulvar cancer expressiveness of activation of antioxidant and glutathione systems is less, than in the primary tumor which may indicate a difference in the oxidative metabolism of the cells in recurrent tumors compared to primary.
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response
Authors: Michele Malagola, Fabio Efficace, Nicola Polverelli, Elisabetta Abruzzese, Alessandra Iurlo, Cristina Bucelli, Fabio Stagno, Massimiliano Bonifacio, Mariella D'adda, Monia Lunghi, Monica Crugnola, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Ferrari Maria Luisa, Micaela Bergamaschi, Gianni Binotto, Rosaria Sancetta, Maria Rosaria Coppi, Valentina Giai, Giovanna Rege Cambrin, Atelda Romano, Mario Tiribelli, Sabina Russo, Lara Aprile, Antonietta Pia Falcone, Serena Rupoli, Antonella Russo Rossi, Emilio Usala, Bruno Martino, Lisa Gandolfi, Simona Bernardi, Camilla Zanaglio, Mirko Farina, Michele Baccarani, Domenico Russo
Journal: Blood (2018)
Inpatient Mortality and Length of Stay Among Direct-Acting Oral Anticoagulant (DOAC) and Warfarin Users Presenting with Major Hemorrhage
Authors: Walter Bialkowski, Sylvia Tan, Alan E. Mast, Joseph Kiss, Daryl J. Kor, Jerome Gottschall, Yanyun Wu, Nareg H. Roubinian, Darrell Triulzi, Steven Kleinman, Young Choi, Donald Brambilla, Ann Butler Zimrin, The NHLBI Recipient Epidemiology and Donor Evaluation Study-III
Journal: Blood (2018)
Tax-Targeting Dendritic Cell Therapy for ATL: A Phase Ia/Ib Clinical Study
Authors: Motoaki Shiratsuchi, Tetsuya Fukuda, Tadafumi Iino, Atsuhiko Hasegawa, Jun-ichirou Yasunaga, Ken Watanabe, Akie Hirata, Hayato Utsunomiya, Hirofumi Ohno, Takashi Ishida, Koichi Akashi, Masao Matsuoka, Mari Kannagi, Youko Suehiro
Journal: Blood (2018)
Abstract 14564: Sex Hormones and Aortic Stiffness
Authors: Vinita Subramanya, Bharath Ambale-Venkatesh, Yoshiaki Ohyama, Di Zhao, Chike C Nwabuo, Wendy S Post, Eliseo Guallar, Pamela Ouyang, Sanjiv J Shah, Matthew Allison, Chiadi E Ndumele, Dhananjay Vaidya, David A Bluemke, Joao A Lima, Erin D Michos
Journal: Circulation (2017)

Background: Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for 50% of all HF cases, with greater prevalence in women. Women experience a steeper decline in aortic elasticity with aging than men, and aortic stiffness correlates with HFpEF risk. These sex differences may relate to sex hormone levels. We hypothesized that a more androgenic pattern, specifically higher free testosterone (T) and lower sex hormone binding globulin (SHBG), would predict greater aortic stiffness in women but not men. Methods: We studied 2080 men and 1868 post-menopausal women aged 45-84 years free of cardiovascular disease, who had serum sex hormone levels, phase contrast cardiac magnetic resonance (CMR) imaging, and an EF>50% at baseline. By CMR, ascending aortic distensibility (AAD), descending aortic distensibility (DAD) and ascending aortic strain (AAS) were determined by the maximum/minimum cross-sectional aortic area. In cross-sectional analyses, we used linear regression, stratified by sex, to determi...
Local excision for stage I anal canal squamous cell carcinoma (ACSCC): A case series from Mayo Clinic.
Authors: Zhaohui Jin, Sakti Chakrabarti, Christopher Leigh Hallemeier, Amit Mahipal
Journal: Journal of Clinical Oncology (2018)

864 Background: Definitive chemoradiotherapy (CRT) is the standard of care for localized or locally advanced ACSCC, while surgery is typically reserved for salvage therapy. Outcome of treatment with local excision alone is unknown and is currently not recommended by NCCN. We retrospectively analyzed outcome of the patients with small (T1 lesion) incidentally found ACSCC who were treated with local excision alone. Methods: On retrospective analysis, a cohort of 12 patients with pathologically confirmed stage I ACSCC treated at Mayo Clinic between 1994 and 2014 was identified who were managed with local excision alone. Baseline as well as followup data were obtained by electronic chart review. Results: Median age of the patients at diagnosis was 68 years (range: 36-81 years) and majority were females (76.9%). Median follow-up duration was 7.5 years. Of the 12 patients, 2 patients did not receive standard CRT due to co-morbid conditions and other 10 patients chose surveillance over CRT. There was only one patient with disease recurrence at 3 years which was salvaged by abdominoperineal resection (APR). This subject remains alive and disease free at the time of data collection (4 years out from APR). There were 4 deaths, all unrelated to ACSCC. Of 12 patients, 10 patients (83%) remained disease free at 5 years and beyond, 1 patient had recurrence and 1 patient was lost to follow up at 5 months from diagnosis. Conclusions: Local excision as a single modality of treatment may be safe and effective for highly selected small stage I ACSCC. Further clinical study is warranted to accurately define the patient population who can be treated with local excision alone, potentially sparing them long term toxicities.
Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity
Authors: Melody Smith, Eric R. Littmann, John B. Slingerland, Annelie Clurman, Ann E. Slingerland, Ying Taur, Jonas Schluter, Jae H. Park, Roisin O'Cearbhaill, Sham Mailankody, Eric L. Smith, Maria Lia Palomba, Oladapo Yeku, Jonathan U. Peled, Elizabeth Halton, Claudia Diamonte, Jason Chan, Malloury Hall, Pavan Anant, Peter Kane, Sergio Giralt, Isabelle Riviere, Renier J. Brentjens, Eric G. Pamer, Marcel R.M. van den Brink
Journal: Blood (2018)
Immune responses induced by the TLR-4 agonist-based adjuvant prothymosin alpha.
Authors: Pinelopi Samara, Kyriaki Ioannou, Nadia Kavrohorianou, Ioannis F. Voutsas, Niki Kappa, Evangelia Williams, Sylva Haralambous, Ourania E. Tsitsilonis
Journal: Journal of Clinical Oncology (2014)

11131 Background: The immunomodulator prothymosin α (proTα) stimulates immune subpopulations via generating an optimized cytokine milieu. The decapeptide proTα(100-109) restores the deficient immune responses of cancer patients in vitro equally well to proTα. ProTα(100-109) and proTα ligate TLR-4, signal through TRIF- and MyD88-dependent pathways, promote the phenotypic and functional maturation of dendritic cells. These elicit TH1-type immune responses and prime tumor antigen-reactive T cell functions. We assessed whether proTα(100-109) and proTα can function similarly in vivo. Methods: PBMCs and cells from various cancer lines incubated with proTα(100-109) or proTα were tested for induction of toxicity/apoptosis by MTT and Annexin V/PI staining. C57BL/6 mice were subcutaneously inoculated with syngeneic melanoma B16.F1 cells and upon palpable tumor formation were intraperitoneally treated with 2 cycles of GM-CSF, proTα(100-109) or proTα, in conjunction with a B16.F1-specific peptide extract (AWE). Tumor growth and animal survival were monitored. Splenocytes from selected animals were tested for their ex vivo cytotoxicity by 51Cr-release assay and CD107 expression. Serum concentrations of IFN-γ and IL-4 were determined. Results: ProTα(100-109) and proTα are not cytotoxic to normal or cancer cells and do not induce PBMC or cancer cell apoptosis/necrosis. In agreement with our in vitro data, both peptides when administered therapeutically in melanoma-bearing mice in the presence of cancer antigens, retard tumor growth and prolong animals’ survival by 25 days. Ex vivo cytotoxicity of mouse splenocytes verified the induction of B16.F1-specific and non-specific responses, mediated by activated cytotoxic T and NK/LAK lymphocytes, respectively. Sera from proTα(100-109) or proTα-treated animals contained more IFN-γ, whereas IL-4 concentration was marginally increased. Conclusions: We propose that the TLR-4 ligands proTα and its immunoactive decapeptide proTα(100-109), induce TH1-biased immune responses to coadministered tumor antigens, both in vitro and in vivo. As they are non-toxic to normal cells, their adjuvanticity to orchestrate anti-tumor immune responses may eventually be used therapeutically.
Activation of CRLF2/IL7RA Signaling in Normal Human Cord Blood Hematopoietic Progenitors Induces Philadelphia-like B-Cell Precursor Pre-Leukemia and Leukemia In Vivo
Authors: Ifat Geron, Angela Maria Savino, Noa Tal, John Brown, Virginia A Turati, Yu Nee Lee, Chela James, Avigail Rein Gil, Yehudit Birger, Inna Muler, Michal Hameiri, Victoria Marcu-Malina, Ute Fischer, Arndt Borkhardt, Ilan M. Kirsch, Arnon Nagler, Tariq Enver, Shai Izraeli
Journal: Blood (2018)
SP0142 What can new insights in the pathogenesis of psoriatic arthritis tell us?
Authors: D. Veale
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> Psoriatic arthritis is a chronic immune-mediated inflammatory arthropathy, of unknown cause that presents with low grade inflammation of the skin, joints and/or entheses including the axial skeleton. Psoriatic arthritis is associated with increased mortality from cardiovascular disease. Diagnosis is primarily according to clinical phenotype due to the diverse clinical features. Increased understanding of the pathogenesis has led to specific new therapeutic agents and treatment strategies that prevent disease progression and improve quality of life, however 40% or more subjects show partial response or fail to respond. Despite this several unmet needs remain. There are no validated biomarkers for diagnosis, prediction of therapeutic response or remission, therefore it remains difficult to accurately assess disease activity, predict which subjects will respond to a specific therapy, and identify those in remission. This review will address specific recent advances in translational research that inform the pathogenesis of psoriatic arthritis. <h3>Disclosure of Interest</h3> None declared
Acute lymphoblastic leukemia treated in Iran: Improving outcome during the last 25 years.
Authors: Hassan Jalaeikhoo, Zohreh Ebrahimnejad, Manoutcheh Keyhani
Journal: Journal of Clinical Oncology (2014)

e18010 Background: Acute lymphoblastic leukemia is a curable disease in most Children . During the last 3 decades there has been changes for better survival in adult .Most of improvement comes from better skill of provider, better design of protocol and patient understanding of the disease , better fallow up and adherence of patient to treatment protocol . Methods: We have treated 438 patents with ALL from 1985 to 2012 .The treatment induction protocol used was the same in all patient .BCR ABL positive received Imatinib 400 mgs per day. We had three groups for consalidation , Group one and two received Brain radiotherapy and intherathecal chemotherapy afer induction .Group 1 (From 1985) with consalidation and maintenace combination consist of mitoxantrone every 135 days Etoposide and Ifosfamide every 35 days for 3 days and 5 days prednisone. In addition methotrexate and 6 -mercaptopurine for 5 days every 14 days. The protocol was continued for 30 months, Group 2 ( from 2001) Patients received consalidation based on the protocol from Birmingam hospital in Great Britain. Group three ( From 2004), received Hyper C-VAD according to original paper in Journal of Clinical Oncology. GCSF treatment started in 2004. Results: Group one: 111 patients, group two: 77 and group three: 250 patients. Group 1. Remission in one month 92 patiens , another 12 patients were in remission in 6 months. Dead in one month 7 patients, in 6 month 5 patients in five yers, 58 patients. Alive 41 patients. In groups 2, 56 patients in remission in one month, remisson in 6 months 13 patients, dead in one month, 2 patients, in 6 months 6 patients in 5 years 34. Alive: 33 patients. Ggroup 3, remission in one month 151, remission in 6 month another 41 patients, no remission 58 patients, dead in one months 16 patients, dead in 6 months 43 patients, in 5 years 57 patients. Alive 128 patients. Conclusions: The best result in this study have been obtained with Hyper-C-VAD protocol after induced remission with the vincristine, daunorubicine. with or without cyclophosphamide and dexamethasone. Side effect of radiotherapy is omitted while using this protocol in patients whiout CNS involvement.
Analysis of patients with two hereditary cancers (breast/ovarian or colon/endometrial) who met NCCN genetic testing criteria after their first cancer.
Authors: Jennifer Saam, Kelsey Moyes, Christopher Arnell, Michelle Landon, Rajesh R. Kaldate, Brian Strike, Kayon Williams, Lynn Anne Burbidge, Brian Abbott
Journal: Journal of Clinical Oncology (2014)

1542 Background: Patients with Hereditary Breast and Ovarian cancer (HBOC) or Lynch syndrome (LS) hereditary cancer syndromes are at a greater risk for developing second cancers after an initial cancer diagnosis. The identification of these patients after the first cancer can lead to the prevention or early identification of second cancers. Methods: We surveyed a commercial laboratory database for BRCA1 and BRCA2 mutations detected among patients with both breast and ovarian cancer tested from Sept. 2006-Oct. 2013. We also reviewed the database for the presence of LS mutations among patients diagnosed with both colon and endometrial cancers who received testing from May 2008-Oct. 2013. We evaluated the prevalence of mutations based on age of diagnosis of the first cancer and examined patient personal cancer history to determine what percentage of the positive patients would have met NCCN guidelines based on the diagnosis of their first cancer (defined as ovarian cancer at any age, breast cancer at age of 45 or less for HBOC, and endometrial or colon cancer less than age 50 for LS). Personal and family history was provided by the health care provider on the test order form. Results: For patients diagnosed with both breast and ovarian cancer (N=9982), the prevalence rate of BRCA1 and BRCA2 mutations was 22.4% (peak mutation rate of 35.8% for patients in their 30s). Of BRCA1 and BRCA2 mutation carriers, 56.0% met criteria for genetic testing after their first cancer—20.5% diagnosed with ovarian cancer first and 35.5% with breast cancer at or under age 45 as their first cancer. Patients diagnosed with colon and endometrial cancer (N=941) had mutations in the LS genes at a prevalence rate of 28.1% (peak mutation rate of 46.7% for patients in their 40s). Of mutation carriers, 65.2% met guidelines for LS testing after the first cancer, 30.7% with colon cancer at age 49 or younger and 34.5% with endometrial cancer younger than age 50. Conclusions: This review of commercial testing data for hereditary cancer syndromes shows the importance of diagnosing patients with hereditary cancer syndromes after their first cancer so a second cancer can be prevented or detected early with improved screening.
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method
Authors: Surbhi Sidana, Dragan Jevremovic, Rhett P. Ketterling, Nidhi Tandon, Angela Dispenzieri, Morie A. Gertz, Patricia T Greipp, Linda B. Baughn, Francis K. Buadi, Martha Q. Lacy, William Morice, Curtis Hanson, Michael Timm, David Dingli, Suzanne R. Hayman, Wilson I. Gonsalves, Prashant Kapoor, Robert A. Kyle, Nelson Leung, Ronald S. Go, John A. Lust, S. Vincent Rajkumar, Shaji K. Kumar
Journal: American Journal of Hematology (2018)

Trisomies of odd numbered chromosomes are seen in nearly half of patients with multiple myeloma (MM) and typically correlate with a hyperdiploid state and better overall survival (OS). We compared DNA ploidy of monoclonal plasma cells (as a surrogate for the presence of trisomies) assessed simultaneously by PCPRO (plasma cell proliferative index), a novel method that estimates DNA index by multi-parametric flow cytometry to fluorescence in situ hybridization (FISH) in 1703 patients with plasma cell disorders. The distribution of ploidy was hyperdiploid: 759 (45%), diploid 765 (45%), hypodiploid: 71 (4%), tetraploid/near-tetraploid: 108 (6%). FISH identified trisomies in 82% (621/756) of patients with hyperdiploidy by PCPRO and no trisomy by FISH was observed in 88% (730/834) of patients without hyperdiploidy. 95% (795/834) of patients without hyperdiploidy on PCPRO had one or less trisomy by FISH. Sensitivity and specificity of PCPRO for detecting hyperdiploidy was 86% (621/725) and 84% (730/865), respectively. Sensitivity increased to 94% (579/618) for patients with more than one trisomy. Newly diagnosed MM patients with hyperdiploidy on PCPRO (147/275) had better OS compared to nonhyperdiploid patients (median not reached vs 59 months, P = 0.008) and better progression free survival (median: 33 vs 23 months, P = 0.03). Within the hyperdiploidy group, patients with high-hyperdiploidy (DNA index: 1.19-1.50) versus those with low-hyperdiploidy (DNA index: 1.05-1.18) had superior OS (3 year OS of 88% vs 68% P = 0.03). Ploidy assessment by flow cytometry can provide rapid, valuable prognostic information and also reduces the number of copy number FISH probes required and hence the cost of FISH.
Variation in use of palliative resection of primary tumor at first presentation of metastatic colorectal cancer within the New Jersey State Cancer Registry.
Authors: Melissa Y Chan, Dirk Moore, Xiaoling Niu, Lisa E. Paddock, Chunxia Chen, Lisa M. Roche, Rebecca Anne Moss
Journal: Journal of Clinical Oncology (2014)

e17602 Background: Palliative resection of the primary tumor (PR) when metastatic colorectal cancer (mCRC) has been documented is of uncertain benefit in the absence of life-threatening symptoms or surgically curable disease. Few studies have assessed use of PR for first presentation of mCRC within a narrow geographic region or outside of the SEER population. Methods: Tumor registry data was obtained from 7,548 pts with histologically confirmed mCRC. Data was derived and analyzed from 73 hospitals in New Jersey from an 11-year period: 2000-2010. The primary endpoint was PR before other therapy, e.g., chemotherapy. Univariate logistic regression analysis was conducted. A descriptive analysis was performed, and a model constructed to control for year of diagnosis and patient factors. All statistical tests are 2-sided. Results: Median age: 69 (range 20-101). Race: Caucasian, 6289; African-American,1050; Hispanic, 640; Asian, 187. 4974 pts underwent upfront PR (65%). Variables associated with lower likelihood of PR are reported in Table. There was no difference by race. Conclusions: Variation in practice across clinical sites demonstrates that in pts with mCRC, PR at first presentation was associated with: insurance status, marital status, gender, fewer comorbidities, and smaller/nonacademic hospitals. PR was less common after 2003. Further analysis of variables influencing survival and use of PR after 2003 is planned and will be presented at the meeting. Characteristics associated with lower likelihood of PR. Lower likelihood of PR Referent P value Patient Sex Male Female 0.014 Age at diagnosis >70 < 70 0.0006 Marital status Single Married <0.0001 Year of diagnosis 2004-2010 2000-2003 <0.0001 Type of insurance Medicaid Private insurance 0.0029 Medicare <0.0001 Uninsured <0.0001 Comorbidities (CoM) (Linear: higher CoM lower likelihood of PR) <0.0001 Hospital Admissions1 >13,772/year 0.042 Outpatient visits1 >150,865/year 0.027 Number of beds >250 100-250 0.009 Teaching affliation2 Major 0.049 Minor <0.0001 ACGME affiliated 0.031 1 upper 2 tertiles v. lowest tertile. 2v. no teaching affiliation.
Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group
Authors: Eirini Katodritou, Efstathios Kastritis, Moshe E. Gatt, Yael C Cohen, Irit Avivi, Anastasia Pouli, Avgi Lalayianni, Noa Lavi, Sossana Delibasi, Marie-Christine Kyrtsonis, Michalis D Michael, Celia Suriu, Miri Zektser, Katrin Herzog Tzarfati, Chrysanthi Vadikolia, Dimitrios Maltezas, Panagiotis Zikos, Chezi Ganzel, Iuliana Vaxman, Ariel Aviv, Anna Christoforidou, Maria Gavriatopoulou, Adir Shaulov, Evgenia Verrou, Aristea-Maria Papanota, Gabriel Fakinos, Annita Ioanna Gkioka, Vasiliki Palaska, Theodora Triantafyllou, Pavlina Konstantinidou, Achilles Anagnostopoulos, Evangelos Terpos, Meletios A Dimopoulos
Journal: Blood (2018)